NAMS
Price
$20.72Alerts
Change
+$1.54 (+8.03%)
Updated
Nov 11 closing price
Capitalization
2.26B
111 days until earnings call
Intraday BUY SELL Signals
PHAT
Price
$6.28Alerts
Change
+$0.83 (+15.23%)
Updated
Nov 11 closing price
Capitalization
424.73M
110 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NAMS vs PHAT

NAMS vs PHAT Comparison Chart in %
View a ticker or compare two or three
VS
NAMS vs. PHAT commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NAMS is a Buy and PHAT is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for NAMS with price predictions
Nov 11, 2026

NAMS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 13, 2026

NAMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 43 cases where NAMS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NAMS's RSI Oscillator exited the oversold zone, 20 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 61 cases where NAMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.

The Moving Average Convergence Divergence (MACD) for NAMS just turned positive on November 11, 2026. Looking at past instances where NAMS's MACD turned positive, the stock continued to rise in 40 of 58 cases over the following month. The odds of a continued upward trend are 69%.

Following a +9.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where NAMS advanced for three days, in 202 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NAMS as a result. In 61 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for NAMS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.578) is normal, around the industry mean (3.498). P/E Ratio (-8.750) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (357.143) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. NAMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for PHAT with price predictions
Nov 11, 2026

PHAT's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for PHAT turned positive on November 11, 2026. Looking at past instances where PHAT's MACD turned positive, the stock continued to rise in 44 of 48 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PHAT's RSI Oscillator exited the oversold zone, 25 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 63 cases where PHAT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on PHAT as a result. In 65 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

Following a +17.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAT advanced for three days, in 248 of 290 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

PHAT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for PHAT entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.234) is normal, around the industry mean (3.498). P/E Ratio (-4.200) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.511) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. PHAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
PHAT: Fundamental Ratings
PHAT
OUTLOOK RATING
1..100
23
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
87
P/E GROWTH RATING
1..100
9
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NAMSPHAT
RSI
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
Bearish Trend 1 day ago
66%
Bullish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
71%
Bullish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
86%
Declines
ODDS (%)
Bearish Trend 10 days ago
78%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
86%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (NAMS: $19.18 vs. PHAT: $5.45)
Brand notoriety: NAMS and PHAT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NAMS: 156% vs. PHAT: 105%
Market capitalization -- NAMS: $2.26B vs. PHAT: $424.73M
NAMS [@Biotechnology] is valued at $2.26B. PHAT’s [@Biotechnology] market capitalization is $424.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NAMS’s FA Score shows that 2 FA rating(s) are green while PHAT’s FA Score has 2 green FA rating(s).

  • NAMS’s FA Score: 2 green, 3 red.
  • PHAT’s FA Score: 2 green, 3 red.
According to our system of comparison, both NAMS and PHAT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NAMS’s TA Score shows that 4 TA indicator(s) are bullish while PHAT’s TA Score has 4 bullish TA indicator(s).

  • NAMS’s TA Score: 4 bullish, 4 bearish.
  • PHAT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both NAMS and PHAT are a good buy in the short-term.

Price Growth

NAMS (@Biotechnology) experienced а -3.62% price change this week, while PHAT (@Biotechnology) price change was -5.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

NAMS is expected to report earnings on Mar 03, 2027.

PHAT is expected to report earnings on Mar 02, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

NAMS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with SLDB. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAMS
1D Price
Change %
NAMS100%
+8.03%
SLDB - NAMS
46%
Loosely correlated
+6.00%
VKTX - NAMS
45%
Loosely correlated
-0.77%
IMVT - NAMS
45%
Loosely correlated
+3.72%
FDMT - NAMS
43%
Loosely correlated
+4.25%
PTCT - NAMS
43%
Loosely correlated
+1.20%
More

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with ALNY. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
+15.34%
ALNY - PHAT
39%
Loosely correlated
+5.41%
QCLS - PHAT
39%
Loosely correlated
-1.91%
ATRA - PHAT
36%
Loosely correlated
+1.60%
NAMS - PHAT
35%
Loosely correlated
+8.03%
STOK - PHAT
34%
Loosely correlated
+2.02%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GEVO1.820.43
+30.94%
Gevo
MNTS1.980.08
+4.21%
Momentus Inc.
DFIN68.680.66
+0.97%
Donnelley Financial Solutions
VMI424.831.45
+0.34%
Valmont Industries
CHSCL24.22-0.05
-0.21%
CHS